KYTX Kyverna Therapeutics, Inc.

NASDAQ
$6.81

Kyverna Therapeutics, Inc. (KYTX) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.0% since its last earnings release on August 11, 2026.

Kyverna Therapeutics Beat Consensus Estimates
Tuesday, August 11, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.68)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.78

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kyverna Therapeutics, Inc.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.